Shimshon Weiss

Shimshon Weiss is the founder and Chief Executive Officer of Israel Bio Fund (israelbiofund.com), a biotech-focused investment vehicle he launched around 2018. In his own words on his professional profile, he is "a fund manager with 30 years+ experience in the investment banking industry," with a focus on biotech and healthcare. Alongside that finance career, public profiles note a long parallel track record as a real estate developer, giving him a background that blends capital markets, deal structuring, and asset development rather than a laboratory-science pedigree.

Through Israel Bio Fund, Weiss positions the firm around a distinctive operating model: rather than raising a blind pool and then deploying it, the fund first sources and selects specific biotech companies and *then* pitches that curated portfolio to investors — an approach he frames as offering a more transparent relationship between the fund and its limited partners. The fund targets biotech businesses in Israel and Europe that are a step more advanced than the earliest-stage startups.

An important note on identity: Weiss's "Israel Bio Fund" is frequently conflated by data aggregators with the similarly named but separate Israel Biotech Fund (ibf.fund), a Rehovot-based clinical-stage biotech VC run by a different management team (whose portfolio includes companies such as Ukko, Cellyrix Therapeutics, and the BioSight exit). Those companies and exits belong to Israel Biotech Fund and should not be attributed to Shimshon Weiss. The details in this profile are limited to what can be tied specifically to Weiss and israelbiofund.com.

• Sector: Concentrated on biotech and healthcare — "My focus is on BioTech and Healthcare" (his own stated bio).
• Stage: Seed round per the known firm data, with the fund's public description emphasizing companies "a bit more advanced than others in the industry" (i.e., somewhat de-risked / mid-to-later relative to raw startups).
• Geography: Israel and Europe.
• Differentiated model: The fund sources and selects portfolio companies *before* raising capital against them, marketing an assembled portfolio to investors for greater transparency.
• What makes him say yes: A finance-and-development lens — he brings 30+ years of investment banking plus real-estate development experience, suggesting he weighs deal structure, capital efficiency, and maturity of the opportunity rather than pure early scientific novelty.